Results 31 to 40 of about 3,975 (165)

Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background HIV infection and abacavir‐containing antiretroviral regimens are associated with vascular endothelial dysfunction and increased cardiovascular risk. Positron emission tomography (PET)‐derived myocardial blood flow reserve (MBFR), the ratio of
Daniel M. Huck, Brittany Weber, Sean Parks, Sanjay Divakaran, Jenifer M. Brown, Courtney F. Bibbo, Leanne Barrett, Jon Hainer, Camden Bay, Laurel Martell, Laura Kogelman, Virginia A. Triant, Jacqueline Chu, Nina H. Lin, Kathleen Melbourne, Paul E. Sax, Marcelo F. Di Carli   +16 more
doaj   +1 more source

Combination therapy with Bictegravir in naive subjects, in subjects already treated with success and virological suppression or in failure: the experience in a single center in Veneto

, 2023
reservedScopo dello studio Questo studio si pone il ]ine di confermare l’ef]icacia della terapia combinata a base di bictegravir nel controllo della viremia e nel miglioramento dei parametri immunologici in due gruppi di pazienti infettati da HIV-1.
TIRON, STEFAN
core  

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials [PDF]

, 2020
Background: In the primary week-48 analyses of two phase 3 studies, coformulated bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to a dolutegravir-containing regimen in treatment-naive people with HIV.
Flamm, JA, Stephens, J.L., Orkin, C., Arribas, J.R., Wohl, D., Martin, H, Thompson, M.A., Clarke, A, DeJesus, E., Wohl, D, Maggiolo, F, Stellbrink, H-J, DeJesus, E, Sax, P.E., Maggiolo, F., Martorell, C, Brainard, D.M., Flamm, J.A., Orkin, C, Martin, H., GS-US-380-1490 study investigators, Martorell, C., Podzamczer, D., Investigator, G-US, Collins, S.E., Brainard, DM, Gupta, SK, Arribas, JR, Hagins, D., GS-US-380-1489 study investigators, Sax, PE, Brinson, C., Acosta, R., Stellbrink, H.-J., Brinson, C, Hagins, D, Podzamczer, D, Gupta, S.K., Stephens, JL, Collins, SE, Thompson, MA, Huang, H, Huang, H., Acosta, R, Clarke, A.   +44 more
core   +2 more sources

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis

Translation, 2023
Please view the PDF to see the formatted meeting abstract.
Abdulmajeed Alharbi
doaj   +1 more source

Bictegravir

, 2018
Purpose of review In this review, we will highlight and discuss the recent efficacy and safety data of bictegravir (BIC), a novel second-generation integrase strand transfer inhibitor (INSTI) that has been recently approved, in coformulation with ...
Spagnuolo, Vincenzo, Vincenzo Spagnuolo, Lazzarin, Adriano, Adriano Lazzarin, Castagna, Antonella, Antonella Castagna   +5 more
core   +1 more source

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

, 2022
In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine ...
Calza L, Miani T, Lazzarotto T, Colangeli V, Viale P, Borderi M, Bon I, Nuti B   +7 more
core   +1 more source

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management

Zhongguo linchuang yanjiu
Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS.
HU Zhiliang, YANG Yongfeng
doaj   +1 more source

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments

Frontiers in Pharmacology, 2020
Bictegravir (BIC) and tenofovir alafenamide fumarate (TAF), two potent anti-HIV drugs, had been nanoformulated (nBIC-TAF) to achieve once-a-month PrEP coverage. In-vivo mouse experiments for nBIC-TAF exhibited favorable subcutaneous (SC) pharmacokinetics.
Simone Perazzolo, Subhra Mandal, Pavan K. Prathipati, Christopher J. Destache   +3 more
doaj   +1 more source

Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants [PDF]

BACKGROUND: Limited data exist on bictegravir pharmacokinetics in pregnancy among persons with HIV (PWH) and infant washout. SETTING: Nonrandomized, open-label, multicenter phase-IV prospective study of bictegravir pharmacokinetics and safety in pregnant
Topete, Lourdes, Knowles, Kevin, Browning, Renee, Huang, Xiaoying, Best, Brookie M, McMorrow, Flynn, Arora, Priyanka, Brooks, Kristina M, Agwu, Allison, Pinilla, Mauricio, Team, the IMPAACT 2026 Protocol, Chakhtoura, Nahida, Stek, Alice, Mirochnick, Mark, Greene, Elizabeth, Powis, Kathleen M, Shapiro, David E, Momper, Jeremiah D, Eke, Ahizechukwu C   +18 more
core   +1 more source

Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Antiretroviral pre‐exposure prophylaxis (PrEP) is less effective in women than expected, partly because drug exposure within the female genital tract is variable and may be influenced by the vaginal microbiome. We developed an integrated pharmacometrics and machine learning framework to evaluate associations between vaginal microbiome composition and ...
Diqin Yan, Lindsey B. Collins, Christopher Staley, Flavia Kiweewa Matovu, Pamala Jacobson, Melanie Nicol, Shen Cheng   +6 more
wiley   +1 more source